New data out for Btk inhibitors Imbruvica, acalabrutinib

Data presented at the American Society of Hematology (ASH) meeting in San Diego showed response rates for Bruton's tyrosine kinase (Btk) inhibitors Imbruvica ibrutinib to treat graft-versus-host disease (GvHD) and acalabrutinib (ACP-196) to treat chronic lymphocytic leukemia (CLL).

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV) market Imbruvica. AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) are developing acalabrutinib...